<DOC>
	<DOCNO>NCT00062348</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure use boronophenylalanine-fructose complex ( BPA-F ) and/or sodium borocaptate ( BSH ) detect presence boron tumor cell may help determine whether patient thyroid cancer , head neck cancer , liver metastasis may benefit boron neutron capture therapy . PURPOSE : This phase I trial study side effect give BPA-F and/or BSH surgery detect boron uptake tissue patient primary , metastatic , recurrent thyroid cancer , head neck cancer , liver metastasis colorectal cancer .</brief_summary>
	<brief_title>Boronophenylalanine-Fructose Complex ( BPA-F ) and/or Sodium Borocaptate ( BSH ) Followed By Surgery Treating Patients With Thyroid Cancer , Head Neck Cancer , Liver Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Identify additional solid tumor may benefit boron neutron capture therapy . - Determine boron concentration tumor , surround tissue , blood patient operable thyroid cancer , squamous cell cancer head neck , liver metastasis secondary colorectal adenocarcinoma receive boronophenylalanine-fructose complex ( BPA-F ) and/or sodium borocaptate ( BSH ) surgical resection . - Determine feasibility use drug obtain favorable absolute boron-10 concentration tumor optimal tumor-to-blood tumor-to-healthy tissue boron-10 rate patient . - Determine qualitative quantitative toxicity combine BPA-F BSH administration patient . OUTLINE : This multicenter study . Patients sequentially assign 1 3 treatment group . - Group I : Patients receive boronophenylalanine-fructose complex ( BPA-F ) IV 1 hour . Two hour later , patient undergo surgical resection . - Group II : Patients receive sodium borocaptate ( BSH ) IV 1 hour . Twelve hour later , patient undergo surgical resection . - Group III : Patients receive BSH IV 1 hour ( administer 12 hour prior surgery ) BPA-F IV 1 hour ( administer 2 hour prior surgery ) . Patients undergo surgical resection . During plan surgery , tissue sample tumor surround tissue collect . Patients follow day 1 5 4 week . PROJECTED ACCRUAL : A maximum 27 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor 1 follow malignant tumor type : Squamous cell cancer head neck Thyroid cancer Liver metastases* secondary colorectal adenocarcinoma NOTE : *Liver metastasis eligible provide colorectal adenocarcinoma histopathologically proven CT scan/MRI show metastatic lesion liver Operable disease surgical excision plan Primary , metastatic , locally recurrent disease PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic Neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic Bilirubin great 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN AST ALT great 2.5 time ULN No severe liver function impairment Renal Creatinine normal BUN normal Cardiovascular No congestive heart failure No angina pectoris No recent coronary artery disease No uncontrolled arrhythmias No conduction defect No severe heart disease Pulmonary No severe obstructive restrictive lung disease Gastrointestinal No severe gastrointestinal disease No active peptic ulcer disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No preexist serious mental organic brain disease ( e.g. , epilepsy ) No history phenylketonuria ( case BPA administration ) No severe allergic disease require continuous medication No concurrent severe disease No uncontrolled endocrine disease No psychological , familial , sociological , geographical condition would preclude study compliance followup PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 3 month since prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy malignant site Surgery See Disease Characteristics Other Recovered prior antitumor therapy ( exclude alopecia ) No concurrent anticancer treatment agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent thyroid cancer</keyword>
	<keyword>stage IV follicular thyroid cancer</keyword>
	<keyword>stage IV papillary thyroid cancer</keyword>
	<keyword>stage IVA colon cancer</keyword>
	<keyword>stage IVB colon cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IVA rectal cancer</keyword>
	<keyword>stage IVB rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>anaplastic thyroid cancer</keyword>
	<keyword>insular thyroid cancer</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>stage I squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage I squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage I papillary thyroid cancer</keyword>
	<keyword>stage II papillary thyroid cancer</keyword>
	<keyword>stage III papillary thyroid cancer</keyword>
	<keyword>stage I follicular thyroid cancer</keyword>
	<keyword>stage II follicular thyroid cancer</keyword>
	<keyword>stage III follicular thyroid cancer</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage I salivary gland cancer</keyword>
	<keyword>stage II salivary gland cancer</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>tongue cancer</keyword>
</DOC>